Skip to main content

Table 2 Intravitreal anti-VEGF injections and renal function

From: Evaluation of long-term intravitreal anti-vascular endothelial growth factor injections on renal function in patients with and without diabetic kidney disease

Clinical VariableAll (n = 85)No DKD (n = 42)DKD (n = 43)P value
Mean No. anti-VEGF injections (SD)26.8 ± 13.228.6 ± 12.525.0 ± 13.80.22
Mean No. ranibizumab injections (SD)16.6 ± 10.017.2 ± 10.416.0 ± 9.70.59
Mean No. aflibercept injections (SD)10.1 ± 6.011.2 ± 4.59.0 ± 7.00.09
Mean baseline eGFR (mL/min/1.73 m2, SD)75.0 ± 21.483.8 ± 13.366.5 ± 24.4< 0.01
Mean follow-up eGFR (mL/min/1.73 m2, SD)65.9 ± 22.975.7 ± 15.957.1 ± 24.6< 0.01
Mean change in eGFR (mL/min/1.73 m2, %)−8.7 (12.1)−8.0 (9.5)−9.4 (14.1)0.56
Mean eGFR slope (mL/min/1.73 m2, SD)−2.6 ± 3.5−2.7 ± 3.4- 2.5 ± 3.60.84
Mean baseline ACR (mg/mmol, SD)17.9 ± 62.11.0 ± 0.6734.4 ± 84.60.01
Mean follow-up ACR (mg/mmol, SD)18.8 ± 48.51.8 ± 2.635.4 ± 64.3< 0.01
Mean change in ACR (mg/mmol, %)+ 0.94 (5.0)+ 0.86 (80)1.0 (2.9)0.99
Mean ACR slope (mg/mmol, SD)0.7 ± 12.30.2 ± 0.71.3 ± 17.40.69
  1. Abbreviations: DKD, diabetic kidney disease; eGFR, estimated glomerular filtration rate; ACR, albumin-to-creatinine ratio; SD, standard deviation